business
Cyber Group Says It Stole Data From Novo Nordisk, FDA Clears Path for Huntington's Treatment
A cyber extortion group reported stealing more than a terabyte of data from Novo Nordisk after an unsuccessful $25 million demand. The FDA reversed an earlier stance and accepted data supporting a marketing application for a Huntington's disease treatment.
marketwatch.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
A cyber extortion group said it stole more than a terabyte of data from Novo Nordisk and is exploring options to sell portions of it. FulcrumSec stated it spent more than two months inside the company's networks. The group said the stolen material includes source code, proprietary drug information, trial data, employee and patient records, facility details, and internal AI model information.
FulcrumSec emerged in October 2025.
It posted a message on its website saying it had demanded $25 million from Novo Nordisk before turning to data sales.
FDA Decision The U.S.
Food and Drug Administration reversed its prior opposition to an experimental Huntington's disease treatment. The agency accepted a three-year analysis from an early-stage study as sufficient to support a marketing application by UniQure. Former agency officials had previously viewed the same data as insufficient for approval.
Transparency
1 source · single source
CorroborationModerate · 1 source
